

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (gh-76)

LENRISPODUN PHOSPHATE

PRONUNCIATION

len" ris poe' dun


THERAPEUTIC CLAIM

Treatment of Parkinson's disease, cardiovascular diseases, and other neurological and cardiovascular diseases

CHEMICAL NAMES

1. Cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2*H*)-one, 2-[[4-(6-fluoro-2-pyridinyl)phenyl]methyl]-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-, (6*aR*,9*aS*)-, phosphate (1:1)
2. (6*aR*,9*aS*)-2-[4-(6-fluoropyridin-2-yl)benzyl]-5-methyl-3-anilino-5,6a,7,8,9,9a-hexahydro-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2*H*)-one phosphate (1:1)

STRUCTURAL FORMULA



MOLECULAR FORMULA

C₂₉H₂₆FN₇O₇.H₃O₄P

MOLECULAR WEIGHT

605.56

TRADEMARK

None as yet

SPONSOR

Intra-Cellular Therapies, Inc.

CODE DESIGNATIONS

ITI-214 phosphate, ITI-214, IC200214 phosphate, IC 200214-12, ITI-002, ITI200214-phosphate, ITI-12-phosphate, ITI-12-Cyclo-(*S,R*) phosphate

CAS REGISTRY NUMBER

1642303-38-5

UNII

YP683YZB8K

gbk